Metformine HCL Pharmacin Pregnancy

• Pregnancy of Metformine HCL Pharmacin in details
• Metformine HCL Pharmacin breastfeeding
• Metformine HCL Pharmacin reviews

Pregnancy of Metformine HCL Pharmacin in details

Metformine HCL Pharmacin crosses the placenta; concentrations may be comparable to those found in the maternal plasma (Charles 2006; de Oliveira Baraldi 2011; Eyal 2010; Vanky 2005).

An increased risk of birth defects or adverse fetal/neonatal outcomes has not been observed following maternal use of Metformine HCL Pharmacin for gestational diabetes mellitus or type 2 diabetes mellitus when glycemic control is maintained (Balani 2009; Coetzee 1979; Coetzee 1984; Ekpebegh 2007; Niromanesh 2012; Rowan 2008; Rowan 2010; Tertti 2008). However, available guidelines note that long-term safety data are not available (ACOG 190 2018; ACOG 201 2018; ADA 2020).

Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major birth defects, stillbirth, and macrosomia (ACOG 201 2018). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2020; Blumer 2013).

Agents other than Metformine HCL Pharmacin are currently recommended to treat diabetes mellitus in pregnancy (ADA 2020). However, Metformine HCL Pharmacin may be used as an alternative agent in some patients requiring therapy for gestational diabetes mellitus or type 2 diabetes mellitus (ACOG 190 2018; ACOG 201 2018). Pharmacokinetic studies suggest that clearance of Metformine HCL Pharmacin may increase during pregnancy and dosing may need adjusted in some women when used during the third trimester (Charles 2006; Eyal 2010; Gardiner 2003; Hughes 2006; Vanky 2005).

Metformine HCL Pharmacin breastfeeding

AU: Use is contraindicated. US and UK: A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Yes Comments: There is limited data available on the effects in the nursing infant.

Drug levels are expected to be 0.5% of their mother's weight-adjusted dosage and are expected to be relatively constant, therefore timing of breastfeeding with drug administration is expected to be of little benefit. In one large study, no adverse effects were observed in breastfed infants. Low detectable serum levels were found in some breastfed infants. This drug should be used with caution while nursing a newborn or premature infant, especially among those with renal impairment.

See references

References for pregnancy information

1. "Product Information. Riomet (Metformine HCL Pharmacin)." Ranbaxy Pharmaceuticals, Jacksonville, FL.
2. "Product Information. Glucophage (Metformine HCL Pharmacin)." Bristol-Myers Squibb, Princeton, NJ.
3. Cerner Multum, Inc. "Australian Product Information." O 0
4. "Product Information. Fortamet (Metformine HCL Pharmacin)." Physicians Total Care, Tulsa, OK.
5. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
6. "Product Information. Glumetza (Metformine HCL Pharmacin)." Biovail Pharmaceuticals Canada, Mississauga, IA.

References for breastfeeding information

1. "Product Information. Glucophage (Metformine HCL Pharmacin)." Bristol-Myers Squibb, Princeton, NJ.
2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
3. Cerner Multum, Inc. "Australian Product Information." O 0
4. "Product Information. Fortamet (Metformine HCL Pharmacin)." Physicians Total Care, Tulsa, OK.
5. "Product Information. Glumetza (Metformine HCL Pharmacin)." Biovail Pharmaceuticals Canada, Mississauga, IA.
6. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
7. "Product Information. Riomet (Metformine HCL Pharmacin)." Ranbaxy Pharmaceuticals, Jacksonville, FL.

References

1. PubMed Health. "Glucophage: This section provide the link out information of drugs collectetd in PubMed Health. ". http://www.ncbi.nlm.nih.gov/pubmedhe... (accessed September 17, 2018).
2. Human Metabolome Database (HMDB). "1,1-Dimethylbiguanide: The Human Metabolome Database (HMDB) is a freely available electronic database containing detailed information about small molecule metabolites found in the human body.". http://www.hmdb.ca/metabolites/HMDB0... (accessed September 17, 2018).
3. FDA Pharm Classes. "FDA Pharmacological Classification: FDA published a final rule that amended the requirements for the content and format of approved labeling (prescribing information) for human prescription drug and biological products in January 2006.". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).

Reviews

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 20 here

Information checked by Dr. Sachin Kumar, MD Pharmacology